Microfluidic Exosome Quantification via Electrochemical Biosensing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and quantifying exosomes, particularly for cancer diagnostics, are inefficient due to their mechanical nature, low sensitivity, and inability to differentiate tumorigenic and non-tumorigenic exosomes effectively, especially at low concentrations found in early cancer stages.
Innovation Solution
The use of microfluidic technology involving droplet or microwell-based methods for the quantification, isolation, and characterization of exosomes by employing capture beads conjugated with specific binding agents and detectable labels, allowing for precise detection and separation of exosomes containing cancer biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods (ultracentrifugation, filtration, density gradient separation) are used for exosome isolation, then exosomes can be isolated from biofluids, but the process is time-consuming and lacks specificity to differentiate tumorigenic and non-tumorigenic exosomes
Solution Approach 1:
The patent replaces mechanical isolation methods (ultracentrifugation, filtration, density gradient separation) with electrical-based methods including electrohydrodynamic systems and electrochemical biosensors. These electrical methods enable specific identification and isolation of tumorigenic exosomes through aptamer-based recognition, significantly reducing isolation time while improving specificity for cancer diagnostics
Solution Approach 2:
The patent introduces aptamers as intermediary molecules that specifically bind to tumorigenic exosomes. These aptamers serve as mediators between the detection system and target exosomes, enabling selective identification and isolation of cancer-associated exosomes from mixed populations, thereby achieving both high specificity and reduced processing time
2Measurement precision
If NTA is used to analyze exosomes, then vesicle number can be measured, but it requires high concentration samples (1×10^7-10^9 particles/mL) and cannot provide accurate measures for low concentration exosomes in early cancer diagnostics
Solution Approach 1:
The patent changes the detection parameters by using electrochemical biosensors with aptamer probes that can detect exosomes at much lower concentrations than NTA. The electrochemical detection method combined with specific aptamer binding enables accurate quantification of low-concentration exosomes (early cancer stages) by measuring electrical signals generated from the aptamer-exosome complex formation
Solution Approach 2:
The patent replaces the optical tracking method of NTA with electrochemical detection methods. This substitution enables detection at lower concentrations because electrochemical biosensors can detect individual binding events with high sensitivity, eliminating the need for high exosome concentrations required by light-scattering-based NTA
3Measurement precision
If Western blot and ELISA are used for exosome analysis, then detailed biomarker information can be obtained, but these methods have poor sensitivity and require large amounts of samples
Solution Approach 1:
The patent replaces Western blot and ELISA mechanical/chemical assays with electrochemical biosensing methods. These electrical-based detection systems provide both high sensitivity for detecting low-concentration exosomes and the capability to identify specific biomarkers, while requiring minimal sample volumes compared to traditional methods
Solution Approach 2:
The patent uses aptamer-based electrochemical sensors that provide localized, specific detection of target biomarkers on exosomes. The aptamers are designed to bind specifically to tumorigenic exosome markers, enabling precise local detection of cancer-related biomarkers with high sensitivity and minimal sample requirement
4Productivity
If flow cytometry is used for exosome sorting, then high throughput sorting can be achieved, but exosomes are often bound to beads and weak light scattering causes number loss
Solution Approach 1:
The patent replaces flow cytometry's light scattering-based detection with electrochemical detection methods. This substitution eliminates the need for bead binding and strong light scattering, allowing for accurate detection and sorting of exosomes at high throughput without the number loss and binding issues inherent in flow cytometry
Data Source
AI summary
Methods of quantification, isolation, and characterization of exosomes are provided. Exosomes can be quantified by contacting a sample with a capture bead comprising a bead and a first binding agent, and a second binding agent. The first binding agent binds to a first biomolecule in the exosomes to produce a first complex and the second binding agent binds to a second biomolecule in the exosomes of the first complex to produce a second complex. The first complexes and the second complexes are quantified based on a detectable signal conjugated to the second binding agent. A microwell or a droplet generation is utilized to quantify the first complexes and the second complexes. Quantifying the exosomes is used to diagnose a cancer in a subject. In such methods, the first and the second binding agents bind to cancer biomarkers present in the exosomes.